ClinicalTrials.gg
CompletedNCT03270384ROBUST-IIUpdated Nov 26, 2025

Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease

An interventional study of Urotronic Drug Coated Balloon (DCB) in Urethral Stricture, sponsored by Urotronic Inc.. Completed at 5 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Urotronic Inc. · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Primary completion was Nov 2019, 7 years ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

The study described below is designed to assess the safety and device performance for the drug coated balloon (DCB) for the treatment of urethral stricture.

02

Conditions studied

  • Urethral Stricture

Browse trials for

Keywords

  • early feasibility
  • non-randomized
03

In context

Urethral Stricture

72 studies on the registry are indexed under Urethral Stricture; 25 are open to participants now.

This study's enrollment of 16 is below the median of 60 across 56 interventional studies indexed under Urethral Stricture.

Browse Urethral Stricture studies →

Lead sponsor

Urotronic Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects ≥ 18 years' old
  2. Visual confirmation of stricture via cystoscopy or urethrogram
  3. Single lesion anterior urethral stricture less than or equal to 3 cm
  4. Two (2) or more prior diagnosis and treatment of stricture treatments (including self-catheterization) including DVIU (direct visual internal urethrotomy), but no prior urethroplasty
  5. Significant symptoms of stricture such as frequency of urination, dysuria, urgency, hematuria, slow flow, feeling of incomplete emptying, recurrent UTI's (urinary tract infections).
  6. IPSS (International Prostate Symptom Score) score of 13 or higher
  7. Lumen diameter \<12F by urethrogram
  8. Able to complete validated questionnaire independently
  9. Qmax \<12 ml/sec
  10. Guidewire must be able to cross the lesion

Exclusion criteria

Exclusion Criteria:

  1. Strictures greater than 3.0 cm long.
  2. Subjects that have more than 1 stricture.
  3. Sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel
  4. Subjects who have a suprapubic catheter
  5. Previous urethroplasty within the anterior urethra
  6. Stricture due to bacterial urethritis or untreated gonorrhea
  7. Stricture dilated or incised within the last 3 months
  8. History of over active bladder or stress incontinence
  9. Previous radical prostatectomy
  10. Previous pelvic radiation
  11. Diagnosed kidney, bladder, urethral or ureteral stones or active stone passage in the past 6 months.
  12. Presence of a penile implant, artificial urinary sphincter, or stent(s) in the urethra or prostate
  13. Known neurogenic bladder, sphincter abnormalities, or poor detrusor muscle function
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment

    Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)

    Device: Urotronic Drug Coated Balloon (DCB)

Interventions

  • DeviceUrotronic Drug Coated Balloon (DCB)

    The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.

06

What researchers measure

Primary outcomes

  1. Safety- Rate of Device Related Serious Complications

    Time frame: 90 days

Secondary outcomes

  1. Safety- Change in IIEF (International Index of Erectile Function)

    Time frame: 90 days

  2. Efficacy- Stricture Recurrence Rate

    Time frame: 6 months

07

Study locations

5 sites
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Chesapeake Urology
    Hanover, Maryland 21076, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Metro Urology
    Woodbury, Minnesota 55125, United States
  • Urology of Virginia
    Virginia Beach, Virginia 23462, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03270384
Lead sponsor
Urotronic Inc.
Responsible party
Sponsor
First posted
Sep 1, 2017
Start date
Oct 25, 2017
Primary completion
Nov 1, 2019
Completion
Feb 19, 2025
Last update
Nov 26, 2025

Study contacts

Sean Elliott, MD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion